You can now read 5 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

US judge allows access to lab in meningitis suit

The New England Compounding Center facility in Framingham is the focus of an inquiry into a fatal meningitis outbreak.

Jared Wickerham/Getty Images

The New England Compounding Center facility in Framingham is the focus of an inquiry into a fatal meningitis outbreak.

A federal judge ruled Wednesday that attorneys representing patients who contracted fungal meningitis will be allowed to conduct their own inspections of the New England Compounding Center while they await word from a federal judicial panel on where the cases will be heard.

Twelve federal lawsuits have been filed in Massachusetts against the drug compounding facility accused of selling tainted steroids that sparked a nationwide fungal meningitis outbreak, and it will be months before anyone knows whether the cases will be heard in Massachusetts and whether they will be consolidated with other lawsuits filed across the country.

Continue reading below

The Judicial Panel on Multi­district Litigation in Washington will hold a hearing Jan. 31 and will issue its decision in February.

In the meantime, US District Judge F. Dennis Saylor IV said Wednesday, attorneys for the plaintiffs will be allowed to begin time-sensitive inspections of the lab’s Framingham facilities.

“We’re either going to do it now, or we’re not going to do it at all,” Saylor said.

Kim Dougherty, an attorney for one of the 12 plaintiffs who filed federal suits in Massachusetts, said patients should not have to wait until February to start their investigation into the facts of the case. Attorneys want to bring in their own experts to conduct an inspection of the lab. By next year, she said, too much time will have elapsed for their results to be useful.

“Time is of the essence,” Dougherty said. “The further along we go to wait to get the sampling, the further it could be compromised.”


Quote Icon

Frederick H. Fern, an attorney for the compounding center, argued that it would be premature for the plaintiffs to conduct inspections before it is determined whether their cases will be consolidated, which could lead to duplicated inspections and conflicting ­results.

“It is too soon, because it flies in the face of the coordination that this case cries out for,” Fern said.

Fern also questioned whether inspections would be fruitful at all, because of the time that has passed since the steroids were produced and the possible effects of heavy traffic from state and federal investigators inside the lab.

“There is no way that the premises now — in any way, shape, or form — show what things were like back in May, June, or July,” Fern said.

Saylor acknowledged he was also “highly skeptical” that attorneys for the plaintiffs will be able to glean accurate conclusions about the lab’s conditions.

But, he said, they deserved an opportunity to try.

Saylor deferred decisions on guidelines and the timing of the inspections to Magistrate Judge Marianne B. ­Bowler. He called for attorneys to coordinate with state and federal investigators who have been conducting inspections of the lab since October.

“I don’t want counsel showing up and tripping over public health authorities,” Saylor said.

Wednesday’s hearing also examined a slew of other decisions that will have to be made in the complex court cases.

Attorneys will meet again Dec. 10 for a status conference.

Martine Powers can be reached at mpowers@
. Follow her on
Twitter @martinepowers.
Loading comments...
Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
Please enter a valid email will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of